Copy number gain and amplification both describe a tumor carrying extra copies of a gene, and the real difference between them is scale. A gain is a modest bump, while an amplification is a heavy, concentrated stack of copies of one small piece of DNA.1PubMed. Gene amplification in cancer On a report, amplification usually carries more weight, because it is more likely to be what drives the cancer and what a targeted drug can act on.2PubMed Central. MET-Dependent Solid Tumors: Molecular Diagnosis and Targeted Therapy Where one ends and the other begins depends on the lab and the test, not on a single rule.
What Extra Gene Copies Mean in a Tumor
Most of your genes come in two copies, one from each parent. That count is called the copy number. Cancer cells often copy or lose pieces of chromosomes as they divide, so the count in a tumor drifts away from two. These changes happen in the tumor only, not in the rest of your body’s cells.
More copies of a gene often mean the cell makes more of that gene’s message and protein.3Thermo Fisher Scientific. The Importance of Detecting Copy Number Variants in the Cancer Genome This link has been seen for well-known cancer genes such as HER2, MET, EGFR, and FGFR1.4PubMed Central. Copy number variation is highly correlated with differential gene expression: a pan-cancer study The match is not perfect, though: in brain tumors, protein levels tracked the gene’s message more closely than its copy count.5PubMed. New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile That is one reason doctors sometimes confirm with a protein stain on the tumor sample.
Your report names specific genes because labs test the ones that matter for treatment. A change in one of these can point toward a specific drug, and a change in a gene that wasn’t tested simply won’t appear.
A gene’s job decides whether extra copies matter. Cancer genes fall roughly into two kinds: growth-promoting genes that act like an accelerator, and protective genes that act like brakes. Reports highlight accelerator genes such as HER2 or EGFR when they are gained. For a brake gene, the worrying change is usually the reverse, a loss of copies, so a gain there is not read the same way. A report is read gene by gene, not by a total count of changes.
A copy number result also says nothing about whether the gene has a typo-like mutation inside it. Those are separate kinds of change and are reported separately. A tumor-only finding is not a verdict on its own; it is weighed with the cancer type, stage, and other test results.
Gain vs. Amplification Side by Side
- Gain: a modest rise above the normal count, for example 3 copies instead of 2.6bionanogenomics. Estimating Copy Number From Log Ratios
- Amplification: a large increase confined to a small stretch of one chromosome arm.7PubMed. Gene amplification in cancer
- One database’s rule: one cancer database calls it amplification when the count is at least double the tumor’s usual baseline, and a gain when it is above baseline but less than double.8NCI Genomic Data Commons. How are the five categories of copy number changes determined?
“Double the baseline” depends on the tumor. Many tumors carry more than two copies of everything, so a count of 4 may be ordinary in such a tumor. Labs adjust for this, which means the same count can be labelled differently from one tumor to the next.
Real tumors show the scale. In one childhood brain cancer, most tumors had 2 to 5 times the normal MYC copies, a low-level gain.9PubMed. Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: utility in predicting prognosis and survival Only a minority went above 5-fold, and very high levels above 10-fold appeared in only the most aggressive subtype.10PubMed. Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: utility in predicting prognosis and survival
A gain often comes from a large chunk of chromosome being copied, so dozens or hundreds of neighboring genes come along for the ride.11Nature Genetics. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers Most are bystanders, and it is hard to know which one, if any, helps the tumor grow. An amplification is concentrated on a small stretch, so it more often points to a single gene the tumor depends on. That is one reason a high-level amplification is more likely to be useful when choosing a drug.
A gain is not automatically harmless, and an amplification is not automatically untreatable; it may open a treatment option. What matters is which gene changed and by how much. Ask your oncologist which category your result falls in and why.
A count called a gain on one report may be called an amplification on another. Qualifiers such as low-level, high-level, or focal amplification often tell you more than the single word does, and the actual number of copies or the ratio is more informative than the label.
How to Read the Numbers on Your Report
Many reports compare the gene’s copies to a marker for its own chromosome. That comparison is the gene-to-chromosome ratio, which your report may list as gene/CEP, and a ratio of 2.0 or more is commonly called amplified.12PubMed Central. Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer Some labs instead call a gain when the average count reaches 4 copies per cell.13PubMed Central. Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer Under the breast-cancer HER2 rules, a result is positive at a ratio of 2.0 or more, or an average of 6 or more copies.14PubMed Central. Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer A ratio under 2 with 4 to under 6 copies is labelled equivocal, meaning borderline.15PubMed Central. Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer
Those HER2 rules apply to breast cancer; a lab may use different rules for other genes or cancers. When comparing reports, compare the same gene, the same cancer, and the same lab’s method.
A typical FISH result lists the average number of gene copies per cell, the average number of chromosome-marker copies per cell, and the gene-to-chromosome ratio calculated from them. Check both numbers, because a result can pass on one rule and fail on another, such as a ratio under 2 with a high average copy count. The final line is usually the interpretation, such as amplified, not amplified, or borderline, and that is the call your team acts on.
The chromosome marker can mislead. Extra copies of it were once blamed on extra whole chromosomes.16Journal of Pathology and Translational Medicine. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation Whole extra chromosomes turned out to be rare, and the marker usually rises from a small local gain near it.17Journal of Pathology and Translational Medicine. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation A high marker count can therefore hide a real amplification by shrinking the ratio.18PubMed. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity In those cases, experts favor using the average copy count.19PubMed. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity
A borderline result is not a final answer. The lab may recount more cells or use a second test, and your care team may also look at protein staining.
Sequencing reports may show a log ratio, where one extra copy is about 0.57 and double is 1.20bionanogenomics. Estimating Copy Number From Log Ratios There is no standard log cutoff, and one study used 0.25 for gain and 0.8 for amplification.21PubMed Central. DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors
Questions worth bringing to your appointment: Was this measured as a ratio or an average count? Which cutoff did this lab use? Does this level qualify me for a targeted drug?
How Labs Measure Copy Number
FISH uses glowing probes to count gene copies in individual tumor cells under a microscope. NGS, or sequencing, estimates copies from DNA read across many cells at once. High-level MET amplification found by FISH matched sequencing results,22PubMed Central. Comparison of MET gene amplification analysis by next-generation sequencing and fluorescence in situ hybridization though one sample with poor sequencing quality gave conflicting results.23PubMed Central. Comparison of MET gene amplification analysis by next-generation sequencing and fluorescence in situ hybridization
Two tests on the same tumor can disagree. Sequencing averages tumor and normal cells together, which can dilute a signal. The glowing-probe test counts cell by cell but samples fewer cells. Low-level gains are where disagreements most often happen, and a retest on fresh tissue may settle the question.
Both tests start from a piece of tumor, usually from a biopsy or surgery that has been preserved in a block of wax. Samples with few tumor cells, or with damaged DNA from age or processing, are harder to read reliably. A pathologist often marks the tumor area first so the lab tests the right part of the tissue.
Some sequencing tests instead look for tumor DNA floating in a blood sample, which helps when a biopsy is difficult or a recheck is needed. Blood tests can miss amplifications if little tumor DNA is shed into the blood, so a negative result there does not always rule out a change. Your team may choose tissue or blood depending on what is practical and what question needs answering.
Why Amplification Level Can Change Treatment
In lung cancer, high-level MET amplification is more likely than low-level gain to mean the tumor depends on MET.24PubMed Central. MET-Dependent Solid Tumors: Molecular Diagnosis and Targeted Therapy With the MET drug capmatinib, 29% of tumors with 10 or more copies shrank.25PubMed Central. Targeting MET Amplification: Opportunities and Obstacles in Therapeutic Approaches Only 12% shrank at 6 to 9 copies, 9% at 4 or 5, and 7% below 4.26PubMed Central. Targeting MET Amplification: Opportunities and Obstacles in Therapeutic Approaches A low-level gain may not be enough to make a targeted drug worthwhile.
A tumor with very many copies may depend on that gene’s signal, so blocking it hits something the tumor relies on. With a low-level gain, the tumor may be driven by something else.
A response rate is the share of people whose tumors shrank. Even at high levels, most tumors did not shrink on this drug alone, and your doctor weighs this alongside other options.
Higher MET levels also predict benefit when MET amplification appears as a way a tumor resists another targeted drug.27PubMed Central. MET-Dependent Solid Tumors: Molecular Diagnosis and Targeted Therapy Tumors can develop new amplifications during treatment, so a new biopsy or blood test may look for them, and the results can change the next treatment choice.
A targeted drug is usually chosen on a combination of the gene result, the cancer type, past treatments, and your overall health. A low-level gain may still lead to a clinical trial, depending on the gene and what is available. If your result is below the level a drug requires, ask whether other findings on the same report point toward a different treatment.
How Amplifications Form and Why Some Shift Over Time
When a chromosome loses its protective tip, broken ends can fuse and break again over many divisions.28PubMed Central. DNA Amplification by Breakage/Fusion/Bridge Cycles Initiated by Spontaneous Telomere Loss in a Human Cancer Cell Line Each cycle can stack extra copies of the same region,29PubMed Central. DNA Amplification by Breakage/Fusion/Bridge Cycles Initiated by Spontaneous Telomere Loss in a Human Cancer Cell Line leaving one cell with extra copies of a segment. These cycles help explain the cell-to-cell variety seen in bone cancer.30PubMed. The breakage-fusion-bridge (BFB) cycle as a mechanism for generating genetic heterogeneity in osteosarcoma
Some amplified genes sit on free-floating DNA circles outside the chromosomes.31PubMed Central. Extrachromosomal DNA amplifications in cancer Because these circles split unevenly at division, some cells inherit far more copies than others.32PubMed Central. Targeting extrachromosomal DNA in human cancers A cell that inherits many copies of a growth gene may outgrow its neighbors, which is how a single tumor can hold cells with very different copy counts. Copy number on the circles can change quickly and reversibly, unlike stable chromosome amplification.33PubMed Central. A recipe for chaos: Extrachromosomal DNA (ecDNA) and the Hallmarks of Cancer The circles have been linked to treatment resistance and shorter survival.34PubMed Central. A recipe for chaos: Extrachromosomal DNA (ecDNA) and the Hallmarks of Cancer During treatment, a targeted gene on the circles can seem to vanish and then return when treatment stops.35PubMed Central. Extrachromosomal DNA in Solid Tumors—Landscape, Immune Effects, and Resistance to Targeted Therapy Cells with fewer copies may survive if the drug is hitting that gene, and then the count rises again later. So a repeat test after treatment may show fewer copies without the change being gone for good.
Gains and amplifications behave differently here. Low-level gains usually sit on chromosomes and stay steady. High-level amplifications are more often on circles or from breakage cycles, which is part of why amplification can be harder to treat over time.
Is a Tumor Gain Something You Inherited
Gains and amplifications on a tumor report come from changes in the cancer cells, not from your parents. Tumor reports test tumor tissue, while inherited testing uses blood or saliva. Everyone also carries inherited copy differences, and some are linked to breast cancer risk.36Nature / Scientific Reports. Germline copy number variations are associated with breast cancer risk and prognosis One inherited deletion was found in 18% of women with breast cancer and 14% of those without.37Nature / Scientific Reports. Germline copy number variations are associated with breast cancer risk and prognosis
Inherited copy differences are present from birth in every cell and most are harmless. The 18% versus 14% comparison shows such a difference may only shift risk slightly.
A tumor amplification will not be found in a relative’s healthy cells, so it gives them no direct information. A gain or amplification in your tumor does not by itself raise your children’s or siblings’ risk, and it is not a reason on its own for family testing. If family history of cancer is strong, ask about genetic counseling.